FDA’s Track for Cell-Based Therapies Added to several other tracks to speed development of therapeutic agents that are safe and effective, the FDA has created a new regulatory pathway for cell-based therapies in regenerative medicine.
No takes yet. Share an insight, caveat, or question.
Marks et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: